Navigation Links
Repligen Elects Glenn L. Cooper, M.D. to the Board of Directors
Date:8/25/2009

WALTHAM, Mass., Aug. 25 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that Glenn L. Cooper, M.D. has been elected to its Board of Directors. Dr. Cooper has extensive leadership experience in the pharmaceutical and biotechnology industries with expertise in transforming development stage companies into commercial organizations. Dr. Cooper was formerly the Chairman and Chief Executive Officer of Indevus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on urology and endocrinology. Under his tenure, Indevus grew from a 25-employee development stage company to a fully integrated pharmaceutical organization with five marketed products, over $100 million in annual sales, and an advanced clinical pipeline. Indevus was acquired by Endo Pharmaceuticals, Inc. in March 2009.

"Dr. Cooper's clinical background and proven business acumen make him an ideal addition to Repligen's Board of Directors," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen. "Through his experience at Indevus, he will provide us with strategic leadership and guidance as we develop innovative products and work to build a sustainable biopharmaceutical company."

Prior to joining Indevus in 1993, Dr. Cooper held numerous executive level positions, including President and Chief Executive Officer of Progenitor, Inc., Executive Vice President and Chief Operating Officer of Sphinx Pharmaceuticals Corporation, and various clinical and regulatory positions with Eli Lilly. Dr. Cooper has participated in the development, approval and commercialization of numerous drugs, including Prozac((R)), Axid((R)), Lorabid((R)), Ceclor((R)), SANCTURA((R)), SANCTURA XR((R)), Supprelin-LA((R)), and Vantas((R)). Dr. Cooper received an M.D. from Tufts University School of Medicine, performed his postdoctoral training in Internal Medicine and Infectious Diseases at the New England Deaconess Hospital and the Massachusetts General Hospital and received a B.A. from Harvard College.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


'/>"/>
SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... New York, NY (PRWEB) , ... May 03, ... ... and NeuroTech NYC , the sensor and data driven conferences, will take ... include:, UnitedHealth's Vidya Raman-Tangella on incorporating technology -- ...
(Date:5/3/2016)... York, NY (PRWEB) , ... May 03, 2016 , ... ... Hill Hospital , for definitive prostate cancer treatment, patients traditionally had two main treatment ... appropriate treatment plan would be made. , New technology has enabled doctors to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Meister ... mind, the fresh look and added functionality give the agricultural world a taste ... a dynamic shift in agriculture – from precision farming via satellites and Unmanned ...
(Date:4/29/2016)... ... ... The MIT bioLogic design team has won multiple A' Design Awards ... be applied to fabric and formed into living interfaces between body and environment. They ... The team harvested Natto cells and applied them to fabric with custom 3D printers.The ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):